-$47M
Value of Insider Transactions in the last 2 years

Sign up to access historical data

Sign up

Insider Transactions

Name Transaction Date Sold / Bought Shares Price Value
Guyer Charles GregNov 12, 2024Sell5,278$66.3743$350,000
Burkhart ErinAug 13, 2024Sell714$90$64,000
Mueller BrianMay 30, 2024Sell5,000$75.19$380,000
Davis George EricMay 28, 2024Sell38,071$74.455$2.8M
Davis George EricMay 28, 2024Sell2,779$75.288$210,000
BIENAIME JEAN JACQUESMay 10, 2024Sell20,000$81.14$1.6M
Davis George EricMay 2, 2024Sell1,850$85.01$160,000
Ajer Jeffrey RobertMay 2, 2024Sell5,000$82.91$410,000
BIENAIME JEAN JACQUESApr 12, 2024Sell20,000$91.26$1.8M
Burkhart ErinApr 10, 2024Sell2,286$90$210,000
Davis George EricMar 28, 2024Sell24,602$88.34$2.2M
BIENAIME JEAN JACQUESMar 6, 2024Sell1,000$86.713$87,000
FUCHS HENRY JMar 5, 2024Sell35,341$85.1814$3M
Ajer Jeffrey RobertMar 5, 2024Sell4,000$87.07$350,000
BIENAIME JEAN JACQUESFeb 27, 2024Sell1,000$90.35$90,000
BIENAIME JEAN JACQUESFeb 9, 2024Sell15,000$88.28$1.3M
BIENAIME JEAN JACQUESJan 10, 2024Sell10,000$96.38$960,000
BIENAIME JEAN JACQUESDec 21, 2023Sell10,000$93.99$940,000
Davis George EricDec 13, 2023Sell13,764$95.3$1.3M
Ajer Jeffrey RobertAug 16, 2023Sell5,000$90$450,000
FUCHS HENRY JAug 10, 2023Sell12,000$90.4259$1.1M
Guyer Charles GregAug 9, 2023Sell5,360$93.304$500,000
Davis George EricAug 8, 2023Sell11,000$89.4238$980,000
BIENAIME JEAN JACQUESAug 8, 2023Sell6,000$88.29$530,000
BIENAIME JEAN JACQUESAug 7, 2023Sell4,000$88.1$350,000
BIENAIME JEAN JACQUESMay 11, 2023Sell24,439$94.55$2.3M
BIENAIME JEAN JACQUESMay 11, 2023Sell5,561$95.22$530,000
BIENAIME JEAN JACQUESMay 10, 2023Sell21,453$94.65$2M
BIENAIME JEAN JACQUESMay 10, 2023Sell8,547$95.34$810,000
BIENAIME JEAN JACQUESMay 9, 2023Sell14,964$95.49$1.4M
BIENAIME JEAN JACQUESMay 9, 2023Sell13,626$94.22$1.3M
BIENAIME JEAN JACQUESMay 9, 2023Sell1,410$95.9$140,000
BIENAIME JEAN JACQUESApr 10, 2023Sell10,000$99.56$1,000,000
BIENAIME JEAN JACQUESApr 6, 2023Sell10,000$96.13$960,000
LAWLIS V BRYANApr 3, 2023Sell8,500$97.09$830,000
BIENAIME JEAN JACQUESMar 13, 2023Sell8,000$90.45$720,000
BIENAIME JEAN JACQUESMar 10, 2023Sell15,000$92.28$1.4M
BIENAIME JEAN JACQUESFeb 13, 2023Sell6,000$109.15$650,000
BIENAIME JEAN JACQUESFeb 10, 2023Sell15,000$110.11$1.7M
Ajer Jeffrey RobertJan 25, 2023Sell44,825$115.654$5.2M
Ajer Jeffrey RobertJan 25, 2023Sell4,175$116.154$480,000
BIENAIME JEAN JACQUESJan 17, 2023Sell10,000$111.55$1.1M
Mueller BrianJan 13, 2023Sell2,500$114.5$290,000
Mueller BrianDec 13, 2022Sell2,500$107.5$270,000
BIENAIME JEAN JACQUESDec 13, 2022Sell1,000$106.89$110,000
Mueller BrianDec 2, 2022Sell3,761$104.5$390,000
Mueller BrianDec 2, 2022Sell2,139$104.5$220,000
Mueller BrianDec 2, 2022Sell1,101$104.5$120,000
BIENAIME JEAN JACQUESDec 2, 2022Sell600$103.971$62,000
BIENAIME JEAN JACQUESDec 2, 2022Sell471$103.97$49,000
BIENAIME JEAN JACQUESDec 2, 2022Sell260$103.98$27,000
BIENAIME JEAN JACQUESDec 2, 2022Sell100$104$10,000
BIENAIME JEAN JACQUESDec 2, 2022Sell69$104.055$7,200
Mueller BrianNov 23, 2022Sell3,500$99.5$350,000
Mueller BrianNov 23, 2022Sell945$99.5$94,000
Mueller BrianNov 23, 2022Sell934$95.09$89,000

What's the latest insider transaction for Biomarin Pharmaceutical?

The most recent insider transaction for Biomarin Pharmaceutical was conducted by Guyer Charles Greg, who sold 5,278 shares on November 12, 2024 at a price of $66.37 per share.

Which insider has sold the most BMRN stock over the last two years?

BIENAIME JEAN JACQUES has sold the most BMRN stock in the last 2 years, with a total value of $24M.

What is the total value of insider transactions for Biomarin Pharmaceutical (BMRN) in the last 2 years?

The total value of insider transactions for Biomarin Pharmaceutical in the last 2 years is negative, amounting to -$47M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.

How do insider transactions over the last 2 years reflect on Biomarin Pharmaceutical's market confidence?

Over the last 2 years, insider transactions for Biomarin Pharmaceutical have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.

Why is monitoring insider trading activity important for investors?

Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.